HK1207654A1 - Modified antibody regions and uses thereof - Google Patents

Modified antibody regions and uses thereof Download PDF

Info

Publication number
HK1207654A1
HK1207654A1 HK15108290.3A HK15108290A HK1207654A1 HK 1207654 A1 HK1207654 A1 HK 1207654A1 HK 15108290 A HK15108290 A HK 15108290A HK 1207654 A1 HK1207654 A1 HK 1207654A1
Authority
HK
Hong Kong
Prior art keywords
modified antibody
antibody regions
regions
modified
antibodies
Prior art date
Application number
HK15108290.3A
Other languages
English (en)
Chinese (zh)
Inventor
Gerhard Frey
Jay M. Short
Hwai Wen Chang
Original Assignee
Bioatla, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla, Llc filed Critical Bioatla, Llc
Publication of HK1207654A1 publication Critical patent/HK1207654A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15108290.3A 2012-04-27 2013-04-26 Modified antibody regions and uses thereof HK1207654A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261639729P 2012-04-27 2012-04-27
US201261639729P 2012-04-27
PCT/US2013/038538 WO2013163630A1 (en) 2012-04-27 2013-04-26 Modified antibody regions and uses thereof

Publications (1)

Publication Number Publication Date
HK1207654A1 true HK1207654A1 (en) 2016-02-05

Family

ID=49483948

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108290.3A HK1207654A1 (en) 2012-04-27 2013-04-26 Modified antibody regions and uses thereof

Country Status (13)

Country Link
US (2) US20150065690A1 (enExample)
EP (2) EP2841458A4 (enExample)
JP (1) JP6470170B2 (enExample)
KR (2) KR20150008082A (enExample)
CN (1) CN104428317B (enExample)
AU (3) AU2013251309B2 (enExample)
BR (1) BR112014026740B1 (enExample)
CA (1) CA2871807C (enExample)
HK (1) HK1207654A1 (enExample)
IN (1) IN2014DN08721A (enExample)
MX (2) MX382840B (enExample)
RU (1) RU2014147741A (enExample)
WO (1) WO2013163630A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459960A (zh) * 2014-05-13 2017-02-22 生物蛋白有限公司 条件活性生物蛋白
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
AU2016370376B2 (en) 2015-12-14 2023-12-14 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
KR102799265B1 (ko) * 2016-03-14 2025-04-23 유니버시티에트 이 오슬로 변경된 FcRn 결합을 갖는 조작된 면역글로불린
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
EP3873940A4 (en) * 2018-10-31 2022-11-30 BioAtla, Inc. ANTI-CTLA4 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNE CONJUGATES AND USES THEREOF
MA54657A (fr) * 2019-01-03 2021-11-10 Invetx Inc Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation
CN113966397A (zh) 2019-03-08 2022-01-21 黑曜石疗法公司 人碳酸酐酶2组合物和用于可调调节的方法
WO2020227515A1 (en) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
WO2021030303A1 (en) 2019-08-12 2021-02-18 Voyager Therapeutics, Inc. High-sensitivity immunoassay for the detection of frataxin in biofluids
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
BR112022019131A2 (pt) * 2020-05-21 2022-11-29 Zydus Lifesciences Ltd Variante fc e composiçâo
EP4139002A2 (en) 2020-05-22 2023-03-01 Formycon AG Ace2-fc fusion proteins and uses thereof
AU2021367988A1 (en) 2020-10-29 2023-05-11 Formycon Ag Ace2 fusion proteins and uses thereof
US20240139296A1 (en) 2021-03-03 2024-05-02 Formycon Ag Formulations of ace2 fc fusion proteins
US20250027067A1 (en) 2021-11-24 2025-01-23 Formycon Ag Improved ace2 fusion proteins
WO2023094571A1 (en) 2021-11-25 2023-06-01 Formycon Ag Stabilization of ace2 fusion proteins
EP4386084A1 (en) 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP4768439B2 (ja) * 2002-10-15 2011-09-07 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2003280247A1 (en) 2002-11-05 2004-06-07 Affinium Pharmaceuticals, Inc. Essential novel bacterial polypeptides
JP2006524039A (ja) * 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
AU2004290070A1 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
CN101189028B (zh) * 2004-07-12 2013-05-29 马克罗基因公司 具有变异Fc区的抗体的鉴定和工程化以及使用方法
DK2471813T3 (en) * 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CN102746404B (zh) 2004-11-12 2016-01-20 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US20100104564A1 (en) * 2005-03-29 2010-04-29 Genevieve Hansen Altered Antibody Fc Regions and Uses Thereof
PL1919503T3 (pl) 2005-08-10 2015-04-30 Macrogenics Inc Identyfikacja i inżynieria przeciwciał ze zmiennymi regionami FC oraz sposoby ich stosowania
CN101331223A (zh) * 2005-10-14 2008-12-24 米迪缪尼有限公司 细胞展示抗体文库
HRP20150279T1 (hr) * 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
CA2726845C (en) * 2008-06-04 2017-09-26 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
CA2750533A1 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
ES2865648T3 (es) 2009-06-26 2021-10-15 Regeneron Pharma Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
TW201206473A (en) * 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8483058B2 (en) 2010-08-17 2013-07-09 Qualcomm Incorporated Systems and methods for traffic policing
CN103648748B (zh) 2011-07-15 2016-03-16 巴塞尔聚烯烃意大利有限责任公司 包含丙烯与1-己烯的无规共聚物的聚烯烃带
MX366269B (es) * 2011-09-30 2019-07-04 Chugai Pharmaceutical Co Ltd Biblioteca de moleculas de union dependientes de la concentracion ionica.
EP2804952A4 (en) * 2012-01-19 2015-09-09 Therapeutic Proteins Int Llc STABILIZATION OF ANTI-CD20 ANTIBODY RITUXIMAB

Also Published As

Publication number Publication date
AU2017225111A1 (en) 2017-09-28
BR112014026740A2 (pt) 2017-06-27
CN104428317B (zh) 2018-08-28
AU2017225111B2 (en) 2019-01-03
CN104428317A (zh) 2015-03-18
KR20200037434A (ko) 2020-04-08
AU2019202229B2 (en) 2021-02-11
AU2019202229A1 (en) 2019-04-18
US20180186863A1 (en) 2018-07-05
KR20150008082A (ko) 2015-01-21
BR112014026740B1 (pt) 2022-10-04
US20150065690A1 (en) 2015-03-05
EP2841458A1 (en) 2015-03-04
EP3470433B1 (en) 2025-12-03
AU2013251309A1 (en) 2014-10-30
EP2841458A4 (en) 2015-09-16
WO2013163630A1 (en) 2013-10-31
MX360368B (es) 2018-10-29
IN2014DN08721A (enExample) 2015-05-22
US10954288B2 (en) 2021-03-23
RU2014147741A (ru) 2016-06-20
CA2871807C (en) 2022-10-04
AU2013251309B2 (en) 2017-06-22
BR112014026740A8 (pt) 2021-06-15
JP2015515497A (ja) 2015-05-28
EP3470433A1 (en) 2019-04-17
CA2871807A1 (en) 2013-10-31
JP6470170B2 (ja) 2019-02-13
MX2014012978A (es) 2015-02-05
MX382840B (es) 2025-03-13

Similar Documents

Publication Publication Date Title
HK1207654A1 (en) Modified antibody regions and uses thereof
IL281731A (en) Humanized antibodies that recognize alpha-synuclein, preparations containing them and their uses
WO2014078268A3 (en) Anti-hemagglutinin antibodies and methods of use
WO2011089183A3 (en) Anticoagulant antidotes
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
WO2014059442A3 (en) Antibody based reagents that specifically recognize toxic oligomeric forms of tau
NZ703423A (en) Antibodies to tau
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
WO2014197849A3 (en) Anti-c10orf54 antibodies and uses thereof
WO2013177055A3 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
HK1218549A1 (zh) 新型抗体框架
HK1210620A1 (en) Multi-specific monoclonal antibodies
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2014150877A3 (en) Anti-tau antibodies and methods of use
WO2014165771A3 (en) Anti-il-4 antibodies and bispecific antibodies and uses thereof
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
EP3091030A4 (en) Anti-human rankl antibody, humanized antibody, pharmaceutical compositions and uses thereof
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
WO2015075269A9 (en) Antibodies against ccr9 and applications thereof
WO2012109238A3 (en) Methods for increasing immune responses using agents that directly bind to and activate ire-1
WO2012058220A3 (en) Anti-sod1 antibodies and uses thereof
TN2013000388A1 (en) Anticoagulant antidotes
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
HK1214279A1 (zh) 組合物和相關的抗原結合蛋白針對il-21受體的方法

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM BIOATLA LLC TO BIOATLA, LLC